Article

[Serum and peritoneal fluid CA-125 concentration in women with endometriosis].

Wolontariusz II Katedry i Kliniki Ginekologii, II Katedry i Kliniki Ginekologii A M we Wrocławiu.
Ginekologia polska (impact factor: 0.41). 12/2001; 72(12A):1365-9. pp.1365-9
Source: PubMed

ABSTRACT To evaluate the clinical utility of CA-125 measurements in peritoneal fluid (PF) as an indicator of endometriosis.
CA-125 levels in paired serum and peritoneal fluid were assessed by IMx CA-125 Assay (ABBOTT).
107 women with and without endometriosis, undergoing laparoscopy during the luteal phase of the menstrual cycle were selected for the study.
CA-125 levels in peritoneal fluid were higher than those found in serum and were significantly elevated (P < 0.05) in comparison to the control group. In women with endometriosis stage I-II and stage III-IV. CA-125 levels in serum were increased only in stage III-IV.
The sensitivity of the peritoneal fluid CA-125 test for endometriosis is higher than the respective serum test. The measurement of CA-125 levels in PF could be useful in the detection of the early stage endometriosis, which seems to be missed by the CA-125 serum test.

0 0
 · 
0 Bookmarks
 · 
19 Views
  • Source
    Article: Urine vascular endothelial growth factor-A is not a useful marker for endometriosis.
    Clariss Potlog-Nahari, Pamela Stratton, Craig Winkel, Eric Widra, Ninet Sinaii, Susan Connors, Lynnette K Nieman
    [show abstract] [hide abstract]
    ABSTRACT: To determine whether urine VEGF is elevated in women with endometriosis. Prospective observational study. Tertiary care government and private hospitals. During laparoscopy for pelvic pain or infertility, urine was collected and possible endometriosis lesions were excised. Of 62 women, 40 had histology-proven endometriosis and 22 had no histological proof of the disease. None. Urine VEGF-A(121, 165) was measured and compared in women with and without biopsy-proven endometriosis. Urine VEGF levels corrected for creatinine excretion were similar in women with (83.6 +/- 11.3 pg/mg Cr) and without (88.5 +/- 10.4 pg/mg Cr) endometriosis (P =.77). The frequency distribution of urine VEGF measurements for women with and without endometriosis was similar. No significant difference was noted in urine VEGF levels when comparing endometriosis stages or in those with endometriomas compared to controls. Urine VEGF did not vary significantly over the menstrual cycle or between groups by cycle phase. No cutoff point discriminated individuals with and without the condition. It is unlikely that urine VEGF-A(121, 165), as measured in this study, will be a useful non-invasive marker for endometriosis.
    Fertility and Sterility 07/2004; 81(6):1507-12. · 3.56 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

ABBOTT
 
CA-125 serum test
 
clinical utility
 
endometriosis
 
endometriosis stage I-II
 
IMx CA-125 Assay
 
luteal phase
 
menstrual cycle
 
paired serum
 
peritoneal fluid
 
peritoneal fluid CA-125 test
 
PF
 
respective serum test
 
stage endometriosis
 
stage III-IV
 
undergoing laparoscopy
 
women
 

D Kraśnicki